BIOV — BioVersys AG Share Price
Last trade - 00:00- CH₣131.38m
- CH₣153.11m
- CH₣0.80m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.2 | ||
| Price to Tang. Book | 2.2 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 164.23 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -24.42% | ||
| Return on Equity | -61.94% | ||
| Operating Margin | -2495.38% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CH₣m | n/a | n/a | n/a | n/a | 0.8 | 3.06 | 4.02 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioVersys AG is a Switzerland based company engaged in the development of biopharmaceuticals. The Company focuses on developing antibacterial therapies to address antimicrobial resistance (AMR), particularly targeting pathogens identified as critical by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). Their key product is BV100, which is a clinical-stage antibacterial compound. It is a small-molecule therapeutic designed to treat serious hospital infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) lung and bloodstream infections. The primary goal of this product is to reduce mortality in intensive care patients where current treatments are ineffective. The Company's portfolio includes also other medicines in various stages of development: BV200, Alpibectir, BV500, BV Discovery.
Directors
- Marc Gitzinger CEO (44)
- Seng Chin Mah NEC (67)
- Glenn Dale OTH (62)
- Hernan Levett CFO (50)
- David Hunstad NED (56)
- Marina Von Schoenau NED (46)
- William Jenkins NED (78)
- Ulrik Schulze NID (59)
- Daniel Ritz CSO (62)
- Last Annual
- December 31st, 2025
- Last Interim
- January 1st, 1970
- Incorporated
- September 24th, 2008
- Public Since
- February 7th, 2025
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- SIX Swiss Exchange
- Shares in Issue
- 5,865,358
- Address
- c/o Technologiepark, Hochbergstrasse 60c, BASEL, 4057
- Web
- https://bioversys.com/
- Phone
- +41 615515120
- Contact
- Hernan Levett
- Auditors
- Ernst & Young Ltd
Latest News for BIOV
Upcoming Events for BIOV
BioVersys AG Annual Shareholders Meeting
Similar to BIOV
Addex Therapeutics
SIX Swiss Exchange
BACHEM HOLDING AG
SIX Swiss Exchange
Basilea Pharmaceutica AG, Allschwil
SIX Swiss Exchange
EvoNext Holdings SA
SIX Swiss Exchange
Idorsia
SIX Swiss Exchange
FAQ
As of Today at 18:39 UTC, shares in BioVersys AG are trading at CH₣22.40. This share price information is delayed by 15 minutes.
Shares in BioVersys AG last closed at CH₣22.40 and the price had moved by -13.18% over the past 365 days. In terms of relative price strength the BioVersys AG share price has underperformed the FTSE Global All Cap Index by -24.4% over the past year.
The overall consensus recommendation for BioVersys AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBioVersys AG does not currently pay a dividend.
BioVersys AG does not currently pay a dividend.
BioVersys AG does not currently pay a dividend.
To buy shares in BioVersys AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CH₣22.40, shares in BioVersys AG had a market capitalisation of CH₣131.38m.
Here are the trading details for BioVersys AG:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: BIOV
Based on an overall assessment of its quality, value and momentum BioVersys AG is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in BioVersys AG is CH₣65.80. That is 193.75% above the last closing price of CH₣22.40.
Analysts covering BioVersys AG currently have a consensus Earnings Per Share (EPS) forecast of -CH₣5.81 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioVersys AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -23.31%.
As of the last closing price of CH₣22.40, shares in BioVersys AG were trading -14.87% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The BioVersys AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CH₣22.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
BioVersys AG's management team is headed by:
- Marc Gitzinger - CEO
- Seng Chin Mah - NEC
- Glenn Dale - OTH
- Hernan Levett - CFO
- David Hunstad - NED
- Marina Von Schoenau - NED
- William Jenkins - NED
- Ulrik Schulze - NID
- Daniel Ritz - CSO